Ahmad, Jawad http://orcid.org/0000-0003-1384-2349
Reddy, K. Rajender
Tillmann, Hans L.
Hayashi, Paul H.
Chalasani, Naga
Fontana, Robert J.
Navarro, Victor J.
Stolz, Andrew
Barnhart, Huiman
Cloherty, Gavin A.
Hoofnagle, Jay H.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (1U01DK100928-01)
Article History
Received: 14 December 2018
Accepted: 12 March 2019
First Online: 29 March 2019
Compliance with Ethical Standards
:
: JA, PHH, AS, VN, HB, JHH: No conflict of interest to disclose. KRR: Scientific Advisory Board-Merck, Abbvie, Gilead, Shionogi, Dova. Research Support (paid to the University of Pennsylvania) Abbvie, Gilead, Merck, Conatus, Intercept, Mallinckrodt. HLT: Abbott stocks from previous employment of Spouse, AbbVie Stocks and employment of spouse, Gilead Stocks, Novartis (DSMB). NC: Consultant for Abbvie, Lilly, Afimmune, NuSirt, Shire, Axovant, Madrigal, Allergan, Immuron and research support from Cumberland, Galectin, Lilly, and Exact Sciences. RJF: Research support from Gilead, BristolMyersSquibb, and Abbvie. Consulted for Alnylam Pharmaceuticals. GAC: Employee and Share Holder or Abbott Laboratories.